CEO John Kao was paid $11,278,583 in fiscal year 2025, ↑ up 77.1% from fiscal year 2024, the 56th percentile of its disclosed peer group (SEC filing 0001628280-26-027058 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$11,278,583 ↑ John Kao total, FY2025 | 56th CEO pay percentile vs peers | 158:1 CEO-to-median pay ratio | 94.82% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
ALHC's next annual pay disclosure, estimated April 23, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| John Kao | $833,654 | $0 | $8,500,014 | $0 | $1,944,495 | $0 | $420 | $11,278,583 |
| Chief Executive Officer | ||||||||
| Dawn Maroney | 676,923 | 0 | 3,700,006 | 0 | 1,053,483 | 0 | 14,420 | 5,444,832 |
| President | ||||||||
| James Head | 394,616 | 0 | 2,500,010 | 0 | 429,302 | 0 | 1,908 | 3,325,835 |
| Chief Financial Officer | ||||||||
| Hyong Kim | 560,000 | 0 | 1,800,016 | 0 | 754,585 | 0 | 14,420 | 3,129,021 |
| Chief Medical Officer | ||||||||
| Christopher Joyce | 525,000 | 0 | 1,750,012 | 0 | 760,435 | 0 | 14,000 | 3,049,447 |
| Chief Legal & Administrative Officer | ||||||||
| Thomas Freeman | 501,923 | 0 | 1,899,990 | 0 | 476,673 | 0 | 8,215 | 2,886,811 |
| Former Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| John Kao | $11,278,583 | $6,369,165 | $14,296,476 | ↑ +4,909,418 |
| Dawn Maroney | 5,444,832 | 3,083,284 | 6,458,999 | ↑ +2,361,548 |
| James Head | 3,325,835 | — | — | — |
| Hyong Kim | 3,129,021 | 2,478,072 | 3,059,277 | ↑ +650,949 |
| Christopher Joyce | 3,049,447 | — | — | — |
| Thomas Freeman | 2,886,811 | 2,848,490 | 6,302,045 | ↑ +38,321 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Alignment Healthcare's Summary Compensation Table. The whole free brief as a PDF, sent in 2 minutes, with every figure cited — then a few short notes on the deeper ALHC reports.
We send the PDF within 2 minutes, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses ALHC in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ALHC in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Dawn Maroney | President | $5,444,832 |
| Christopher Joyce | General Counsel | $3,049,447 |
| Hyong Kim | Chief Medical Officer | $3,129,021 |
| James Head | CFO | $3,325,835 |
| John Kao | CEO | $11,278,583 |
| Thomas Freeman | CFO | $2,886,811 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| David Hodgson | Independent Director | $310,000 |
| Jacqueline Kosecoff | Independent Director | $322,500 |
| Jody Bilney | Independent Director | $305,000 |
| Joseph Konowiecki | Chair of the Board | $490,000 |
| Margaret McCarthy | Independent Director | $355,000 |
| Mark McClellan | Independent Director | $297,500 |
| Robbert Vorhoff | Independent Director | $300,000 |
| Yon Jorden | Independent Director | $320,000 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| John Kao | Director | 2026-05-11 | D | 17,107 | $18 | $299,971 | Common | Form 4 ↗ |
| John Kao | Director | 2026-05-11 | D | 280,893 | 17 | 4,732,879 | Common | Form 4 ↗ |
| Dawn Maroney | President | 2026-05-15 | D | 1,500 | 0 | 0 | Common | Form 4 ↗ |
| Dawn Maroney | President | 2026-05-15 | D | 30,000 | 16 | 482,565 | Common | Form 4 ↗ |
| Dawn Maroney | President | 2026-05-18 | D | 20,000 | 0 | 0 | Common | Form 4 ↗ |
| Mark D. Kent | President - MSO | 2026-06-02 | A | 14,848 | 13 | 197,627 | Common | Form 4 ↗ |
| Mark D. Kent | President - MSO | 2026-06-03 | A | 87,719 | 0 | 0 | Common | Form 4 ↗ |
| Joseph Konowiecki | Director | 2026-06-03 | A | 122,807 | 0 | 0 | Common | Form 4 ↗ |
| John Kao | Director | 2026-06-10 | D | 223,064 | 21 | 4,594,271 | Common | Form 4 ↗ |
| John Kao | Director | 2026-06-10 | D | 74,936 | 20 | 1,472,350 | Common | Form 4 ↗ |
| Joseph Konowiecki | Director | 2026-06-11 | D | 25,000 | 21 | 525,000 | Common | Form 4 ↗ |
| Hyong Kim | Chief Medical Officer | 2026-06-12 | D | 35,951 | 20 | 713,947 | Common | Form 4 ↗ |
| Dawn Maroney | President | 2026-06-15 | D | 30,000 | 20 | 586,425 | Common | Form 4 ↗ |
| Joseph Konowiecki | Director | 2026-06-18 | D | 25,000 | 22 | 550,000 | Common | Form 4 ↗ |
| Joseph Konowiecki | Director | 2026-06-26 | D | 25,000 | 23 | 575,000 | Common | Form 4 ↗ |
| Joseph Konowiecki | Director | 2026-07-01 | D | 25,000 | 24 | 600,000 | Common | Form 4 ↗ |
| Shane J. Hochradel | Chief Operations Officer | 2026-07-01 | A | 87,719 | 0 | 0 | Common | Form 4 ↗ |
| John Kao | Director | 2026-07-10 | D | 18,356 | 21 | 378,998 | Common | Form 4 ↗ |
| John Kao | Director | 2026-07-10 | D | 279,644 | 20 | 5,540,363 | Common | Form 4 ↗ |
| Dawn Maroney | President | 2026-07-15 | D | 177,068 | 21 | 3,687,990 | Common | Form 4 ↗ |
| Dawn Maroney | President | 2026-07-15 | A | 152,068 | 9 | 1,377,736 | Common | Form 4 ↗ |
| Dawn Maroney | President | 2026-07-15 | D | 152,068 | 9 | 1,377,736 | Derivative, Class A Common | Form 4 ↗ |
| John Kao | Director | 2026-08-10 | D | 298,000 | 14 | 4,136,776 | Common | Form 4 ↗ |
| Dawn Maroney | President | 2026-08-14 | D | 5,000 | 14 | 70,000 | Common | Form 4 ↗ |
| John Kao | Director | 2026-09-10 | D | 172,600 | 13 | 2,236,447 | Common | Form 4 ↗ |
| Dawn Maroney | President | 2026-09-11 | D | 122,707 | 13 | 1,555,925 | Common | Form 4 ↗ |
| John Kao | Director | 2026-09-11 | D | 385,270 | 13 | 4,885,224 | Common | Form 4 ↗ |
| John Kao | Director | 2026-09-14 | D | 27,400 | 13 | 356,200 | Common | Form 4 ↗ |
| Joseph Konowiecki | Director | 2026-09-17 | D | 23,511 | 9 | 202,430 | Common | Form 4 ↗ |
| Hyong Kim | Chief Medical Officer | 2026-10-06 | D | 32,479 | 8 | 269,576 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Thomas Freeman | PSU | 2025-03-13 | 30,645 | 61,290 | — | 122,580 | $949,995 |
| Dawn Maroney | PSU | 2025-03-13 | 59,678 | 119,355 | — | 238,710 | 1,850,003 |
| James Head | RSU | 2025-06-04 | — | — | 81,593 | — | 1,250,005 |
| James Head | PSU | 2025-06-04 | 40,797 | 81,593 | — | 163,186 | 1,250,005 |
| Christopher Joyce | RSU | 2025-03-13 | — | — | 56,452 | — | 875,006 |
| Christopher Joyce | PSU | 2025-03-13 | 28,226 | 56,452 | — | 112,904 | 875,006 |
| Hyong Kim | RSU | 2025-03-13 | — | — | 58,065 | — | 900,008 |
| Thomas Freeman | RSU | 2025-03-13 | — | — | 61,290 | — | 949,995 |
| John Kao | PSU | 2025-03-13 | 137,097 | 274,194 | — | 548,388 | 4,250,007 |
| John Kao | RSU | 2025-03-13 | — | — | 274,194 | — | 4,250,007 |
| Hyong Kim | PSU | 2025-03-13 | 29,033 | 58,065 | — | 116,130 | 900,008 |
| Dawn Maroney | RSU | 2025-03-13 | — | — | 119,355 | — | 1,850,003 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Thomas Freeman | $949,995 | $949,995 | $0 | 50.0% |
| Dawn Maroney | 1,850,003 | 1,850,003 | 0 | 50.0% |
| James Head | 1,250,005 | 1,250,005 | 0 | 50.0% |
| Christopher Joyce | 875,006 | 875,006 | 0 | 50.0% |
| Hyong Kim | 900,008 | 900,008 | 0 | 50.0% |
| John Kao | 4,250,007 | 4,250,007 | 0 | 50.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Dawn Maroney | RSU | 97,500 | — | $1,925,625 |
| John Kao | PSU | 274,194 | — | 5,415,332 |
| John Kao | PSU | 819,513 | — | 16,185,382 |
| John Kao | PSU | 330,000 | — | 6,517,500 |
| John Kao | RSU | 247,500 | — | 4,888,125 |
| Dawn Maroney | PSU | 215,661 | — | 4,259,305 |
| Hyong Kim | RSU | 170,068 | — | 3,358,843 |
| Hyong Kim | PSU | 140,000 | — | 2,765,000 |
| Dawn Maroney | PSU | 130,000 | — | 2,567,500 |
| Christopher Joyce | PSU | 130,000 | — | 2,567,500 |
| Thomas Freeman | PSU | 61,290 | — | 1,210,478 |
| John Kao | PSU | 124,172 | — | 2,452,397 |
| Christopher Joyce | RSU | 122,511 | — | 2,419,592 |
| Dawn Maroney | PSU | 119,355 | — | 2,357,261 |
| Thomas Freeman | PSU | 110,000 | — | 2,172,500 |
| Hyong Kim | PSU | 105,000 | — | 2,073,750 |
| Christopher Joyce | RSU | 97,500 | — | 1,925,625 |
| James Head | PSU | 81,593 | — | 1,611,462 |
| Hyong Kim | PSU | 58,065 | — | 1,146,784 |
| Christopher Joyce | PSU | 56,452 | — | 1,114,927 |
| Thomas Freeman | RSU | 55,000 | — | 1,086,250 |
| Dawn Maroney | RSU | 51,738 | — | 1,021,826 |
| Thomas Freeman | PSU | 40,860 | — | 806,985 |
| John Kao | Option | 91,241 | 9.06 | — |
| Dawn Maroney | Option | 38,017 | 9.06 | — |
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | FW Cook |
| Clawback policy | — |
| Anti-hedging | — |
| Anti-pledging | — |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-04 | 169,068,300 | 8,701,941 | 542,191 | 94.82% | Passed |
| 2025 | 2025-06-05 | 162,732,057 | 1,840,930 | 494,523 | 98.59% | Passed |
| 2024 | 2024-06-07 | 138,403,746 | 21,289,607 | 5,882 | 86.67% | Passed |
| 2023 | 2023-06-06 | 110,852,417 | 54,729,829 | 277,422 | 66.84% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-04 | 94.82%a |
| 2025 | 2025-06-05 | 98.59%b |
| 2024 | 2024-06-07 | 86.67%c |
a. Approved under the standard stated in the filing — “(4) Abstentions will be counted as present and entitled to vote on the proposals and will therefore have the effect of a negative vote.”.
b. Approved under the standard stated in the filing — “(4) Abstentions will be counted as present and entitled to vote on the proposals and will therefore have the effect of a negative vote.”.
c. Approved under the standard stated in the filing — “Abstentions will be counted as present and entitled to vote on the proposals and will therefore have the effect of a negative vote.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 158 : 1 |
|---|---|
| CEO total compensation | $11,278,583 |
| Median employee compensation | $71,260 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Joseph KonowieckiNot independent · Board Chair · Compensation | $100,000 | $390,000 | $0 | $0 | $0 | $490,000 |
| Margaret McCarthyIndependent · Audit Committee · Compensation Committee | 145,000 | 210,000 | 0 | 0 | 0 | 355,000 |
| Jacqueline KosecoffIndependent · Compensation Committee (Chair) · NCGCC | 132,500 | 190,000 | 0 | 0 | 0 | 322,500 |
| Yon JordenIndependent · Audit (Chair) · Compensation | 130,000 | 190,000 | 0 | 0 | 0 | 320,000 |
| David HodgsonIndependent · NCGCC (Chair) | 20,000 | 290,000 | 0 | 0 | 0 | 310,000 |
| Jody BilneyIndependent · Audit Committee | 65,000 | 240,000 | 0 | 0 | 0 | 305,000 |
| Robbert VorhoffIndependent · Compensation Committee | 10,000 | 290,000 | 0 | 0 | 0 | 300,000 |
| Mark McClellanIndependent · NCGCC | 107,500 | 190,000 | 0 | 0 | 0 | 297,500 |
| John KaoEmployee director · Compensation | 0 | 0 | 0 | 0 | 0 | 0 |
| Annual cash retainer | $0 |
|---|---|
| Annual equity retainer | $250,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 20,000 |
| Stock ownership guideline | $500,000 |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $710,000 |
| Equity awards (grant-date value) | $1,990,000 |
| All other compensation | $0 |
| Total cost of the board | $2,700,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Alignment Healthcare names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Alignment Healthcare.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Bausch & Lomb Corp. | 2025 | Brenton Saunders | $1,600,000 | $23,778,578 | $2,799,998 | $4,000,000 | $32,194,326 |
| 2 | DaVita Inc. | 2025 | Javier Rodriguez | 1,500,000 | 11,442,481 | 2,699,982 | 2,089,491 | 18,210,597 |
| 3 | Quest Diagnostics Inc. | 2025 | James Davis | 1,250,000 | 8,762,861 | 2,999,873 | 2,205,844 | 15,498,479 |
| 4 | Astrana Health, Inc. | 2025 | Brandon Sim | 850,000 | 11,999,980 | 0 | 2,059,125 | 14,930,231 |
| 5 | Evolent Health, Inc. | 2025 | Seth Blackley | 867,068 | 12,699,086 | 0 | 0 | 14,240,154 |
| 6 | Ensign Group, Inc. | 2025 | Barry Port | 549,264 | 2,912,355 | 0 | 10,317,247 | 13,804,700 |
| 7 | RadNet, Inc. | 2025 | Howard Berger | 3,000,000 | 8,999,966 | 0 | 0 | 12,087,934 |
| 8 | Alignment Healthcare | 2025 | John Kao | 833,654 | 8,500,014 | 0 | 1,944,495 | 11,278,583 |
| 9 | Teladoc Health, Inc. | 2025 | Charles Divita, III | 800,000 | 9,699,996 | 0 | 584,000 | 11,202,996 |
| 10 | Privia Health Group, Inc. | 2025 | Parth Mehrotra | 650,000 | 8,588,373 | 0 | 1,218,750 | 10,472,698 |
| 11 | AdaptHealth Corp. | 2025 | Suzanne Foster | 1,000,000 | 7,530,880 | 0 | 1,394,694 | 10,256,240 |
| 12 | Option Care Health, Inc. | 2025 | John Rademacher | 1,000,000 | 6,500,050 | 0 | 1,665,000 | 9,266,330 |
| 13 | agilon health, inc. | 2025 | Jeffrey Schwaneke | 625,000 | 2,950,003 | 1,750,000 | 271,875 | 5,610,878 |
| 14 | Select Medical Holdings Corp. | 2025 | Thomas Mullin | 618,000 | 1,425,000 | 0 | 939,360 | 3,042,527 |
| 15 | Pediatrix Medical Group, Inc. | 2025 | James Swift | 54,167 | 730,720 | 0 | 68,981 | 2,775,881 |
| 16 | Clover Health Investments Corp. | 2025 | Andrew Toy | 800,000 | 0 | 0 | 509,539 | 1,319,385 |
| 17 | Oscar Health, Inc. | 2025 | Mark Bertolini | 619,178 | 0 | 0 | 169,036 | 1,149,308 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Alignment Healthcare | 200% | not disclosed | No | FW Cook |
| AdaptHealth Corp. | 116.22% | PSU 50 · RSU 50 | Yes — Relative TSR | ClearBridge |
| agilon health, inc. | 58% | not disclosed | No | Semler Brossy |
| Astrana Health, Inc. | 193.8% | PSU 67 · RSU 33 | No | Pearl Meyer |
| Bausch & Lomb Corp. | 100% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (rTSR) | Pay Governance |
| Clover Health Investments Corp. | 64% | RSU 60 · Cash LTI 40 | No | Aon, plc (Human Capital Practice) |
| DaVita Inc. | 93% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR v. S&P Health Care Services Select Industry Index | Compensia |
| Ensign Group, Inc. | not disclosed | not disclosed | not disclosed | Willis Towers Watson |
| Evolent Health, Inc. | 75% | PSU 70 · RSU 30 | No | Exequity |
| Option Care Health, Inc. | 111% | PSU 60 · RSU 40 | No | Pearl Meyer |
| Oscar Health, Inc. | 91.0% | PSU 50 · RSU 50 | Yes — Relative TSR | FW Cook |
| Pediatrix Medical Group, Inc. | 180% | PSU 50 · RSU 50 | No | Semler Brossy Consulting Group |
| Privia Health Group, Inc. | 150% | PSU 60 · RSU 40 | No | Korn Ferry (through September 2025), WTW (starting September 2025) |
| Quest Diagnostics Inc. | 113.9% | PSU 50 · RSU 25 · Options 25 | Yes — Relative TSR | Semler Brossy |
| RadNet, Inc. | not disclosed | RSU 100 | No | Pearl Meyer |
| Select Medical Holdings Corp. | 190% | RSU 100 | not disclosed | not disclosed |
| Teladoc Health, Inc. | 73% | RSU 50 · PSU 50 | No | Aon |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, John Kao | DEF 14A | 2026-04-24 | 0001628280-26-027058 | Section “Executive Compensation”. As printed: 11,278,583. Filing ↗machine: r2 · c21 · span 656828–656838 |
| 2 | Section 01, Dawn Maroney | DEF 14A | 2026-04-24 | 0001628280-26-027058 | Section “Executive Compensation”. As printed: 5,444,832. Filing ↗machine: r5 · c21 · span 663324–663333 |
| 3 | Section 01, James Head | DEF 14A | 2026-04-24 | 0001628280-26-027058 | Section “Executive Compensation”. As printed: 3,325,835. Filing ↗machine: r8 · c21 · span 669777–669786 |
| 4 | Section 01, Hyong Kim | DEF 14A | 2026-04-24 | 0001628280-26-027058 | Section “Executive Compensation”. As printed: 3,129,021. Filing ↗machine: r12 · c21 · span 678841–678850 |
| 5 | Section 01, Christopher Joyce | DEF 14A | 2026-04-24 | 0001628280-26-027058 | Section “Executive Compensation”. As printed: 3,049,447. Filing ↗machine: r15 · c21 · span 685883–685892 |
| 6 | Section 01, Thomas Freeman | DEF 14A | 2026-04-24 | 0001628280-26-027058 | Section “Executive Compensation”. As printed: 2,886,811. Filing ↗machine: r9 · c21 · span 672510–672519 |
| 7 | Section 03, Thomas Freeman PSU | DEF 14A | 2026-04-24 | 0001628280-26-027058 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 752372–752379 |
| 8 | Section 03, Dawn Maroney PSU | DEF 14A | 2026-04-24 | 0001628280-26-027058 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 731116–731125 |
| 9 | Section 03, James Head RSU | DEF 14A | — | 0001628280-26-027058 | Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t92 · r23 · c9 · span 853766–853772 |
| 10 | Section 03, James Head PSU | DEF 14A | — | 0001628280-26-027058 | Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t92 · r23 · c9 · span 853766–853772 |
| 11 | Section 03, Christopher Joyce RSU | DEF 14A | 2026-04-24 | 0001628280-26-027058 | Section “EACH OF THE ABOVE DIRECTOR NOMINEES.” · grants of plan-based awards table. Filing ↗machine: t84 · r7 · c2 · span 600349–600356 |
| 12 | Section 03, Christopher Joyce PSU | DEF 14A | 2026-04-24 | 0001628280-26-027058 | Section “EACH OF THE ABOVE DIRECTOR NOMINEES.” · grants of plan-based awards table. Filing ↗machine: t84 · r7 · c2 · span 600349–600356 |
| 13 | Section 03, Hyong Kim RSU | DEF 14A | 2026-04-24 | 0001628280-26-027058 | Section “EACH OF THE ABOVE DIRECTOR NOMINEES.” · grants of plan-based awards table. Filing ↗machine: t84 · r6 · c2 · span 599391–599398 |
| 14 | Section 03, Thomas Freeman RSU | DEF 14A | 2026-04-24 | 0001628280-26-027058 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 15 | Section 03, John Kao PSU | DEF 14A | 2026-04-24 | 0001628280-26-027058 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 718638–718647 |
| 16 | Section 03, John Kao RSU | DEF 14A | 2026-04-24 | 0001628280-26-027058 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 715815–715824 |
| 17 | Section 03, Hyong Kim PSU | DEF 14A | 2026-04-24 | 0001628280-26-027058 | Section “EACH OF THE ABOVE DIRECTOR NOMINEES.” · grants of plan-based awards table. Filing ↗machine: t84 · r6 · c2 · span 599391–599398 |
| 18 | Section 03, Dawn Maroney RSU | DEF 14A | 2026-04-24 | 0001628280-26-027058 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 19 | Section 07, pay ratio | DEF 14A | 2026-04-24 | 0001628280-26-027058 | Section “CEO Pay Ratio”. As printed: 158 : 1. Filing ↗machine: span 1158270–1158273 |
| 20 | Section 08, Joseph Konowiecki | DEF 14A | 2026-04-24 | 0001628280-26-027058 | Section “Director Compensation”. As printed: 490,000. Filing ↗machine: span 1041488–1041608 |
| 21 | Section 08, Margaret McCarthy | DEF 14A | 2026-04-24 | 0001628280-26-027058 | Section “Director Compensation”. As printed: 355,000. Filing ↗machine: span 1044025–1044145 |
| 22 | Section 08, Jacqueline Kosecoff | DEF 14A | 2026-04-24 | 0001628280-26-027058 | Section “Director Compensation”. As printed: 322,500. Filing ↗machine: span 1042820–1042940 |
| 23 | Section 08, Yon Jorden | DEF 14A | 2026-04-24 | 0001628280-26-027058 | Section “Director Compensation”. As printed: 320,000. Filing ↗machine: span 1040183–1040303 |
| 24 | Section 08, David Hodgson | DEF 14A | 2026-04-24 | 0001628280-26-027058 | Section “Director Compensation”. As printed: 310,000. Filing ↗machine: span 1038860–1038980 |
| 25 | Section 08, Jody Bilney | DEF 14A | 2026-04-24 | 0001628280-26-027058 | Section “Director Compensation”. As printed: 305,000. Filing ↗machine: span 1037535–1037655 |
| 26 | Section 08, Robbert Vorhoff | DEF 14A | 2026-04-24 | 0001628280-26-027058 | Section “Director Compensation”. As printed: 300,000. Filing ↗machine: span 1046754–1046874 |
| 27 | Section 08, Mark McClellan | DEF 14A | 2026-04-24 | 0001628280-26-027058 | Section “Director Compensation”. As printed: 297,500. Filing ↗machine: span 1045352–1045472 |
| 28 | Section 08, John Kao | DEF 14A | 2026-04-24 | 0001628280-26-027058 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 29 | Section 02, John Kao 2026-05-11 | Form 4 | 2026-05-13 | 0001628280-26-034621 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, John Kao 2026-05-11 | Form 4 | 2026-05-13 | 0001628280-26-034621 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Dawn Maroney 2026-05-15 | Form 4 | 2026-05-19 | 0001628280-26-036489 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Dawn Maroney 2026-05-15 | Form 4 | 2026-05-19 | 0001628280-26-036489 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Dawn Maroney 2026-05-18 | Form 4 | 2026-05-19 | 0001628280-26-036489 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Mark D. Kent 2026-06-02 | Form 4 | 2026-06-02 | 0001628280-26-040005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Mark D. Kent 2026-06-03 | Form 4 | 2026-06-09 | 0001628280-26-041913 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Joseph Konowiecki 2026-06-03 | Form 4 | 2026-06-09 | 0001628280-26-041910 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, John Kao 2026-06-10 | Form 4 | 2026-06-12 | 0001628280-26-042824 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, John Kao 2026-06-10 | Form 4 | 2026-06-12 | 0001628280-26-042824 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Joseph Konowiecki 2026-06-11 | Form 4 | 2026-06-12 | 0001628280-26-042830 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Hyong Kim 2026-06-12 | Form 4 | 2026-06-15 | 0001628280-26-043335 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Dawn Maroney 2026-06-15 | Form 4 | 2026-06-15 | 0001628280-26-043369 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Joseph Konowiecki 2026-06-18 | Form 4 | 2026-06-18 | 0001628280-26-044253 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Joseph Konowiecki 2026-06-26 | Form 4 | 2026-06-26 | 0001628280-26-045734 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Joseph Konowiecki 2026-07-01 | Form 4 | 2026-07-01 | 0001628280-26-046575 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Shane J. Hochradel 2026-07-01 | Form 4 | 2026-07-02 | 0001628280-26-046944 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, John Kao 2026-07-10 | Form 4 | 2026-07-14 | 0001628280-26-048170 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, John Kao 2026-07-10 | Form 4 | 2026-07-14 | 0001628280-26-048170 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Dawn Maroney 2026-07-15 | Form 4 | 2026-07-16 | 0001628280-26-048498 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Dawn Maroney 2026-07-15 | Form 4 | 2026-07-16 | 0001628280-26-048498 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Dawn Maroney 2026-07-15 | Form 4 | 2026-07-16 | 0001628280-26-048498 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, John Kao 2026-08-10 | Form 4 | 2026-08-10 | 0001628280-26-055418 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Dawn Maroney 2026-08-14 | Form 4 | 2026-08-18 | 0001628280-26-057635 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, John Kao 2026-09-10 | Form 4 | 2026-09-11 | 0001628280-26-061620 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Dawn Maroney 2026-09-11 | Form 4 | 2026-09-11 | 0001628280-26-061621 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, John Kao 2026-09-11 | Form 4 | 2026-09-11 | 0001628280-26-061620 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, John Kao 2026-09-14 | Form 4 | 2026-09-16 | 0001628280-26-062329 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Joseph Konowiecki 2026-09-17 | Form 4 | 2026-09-18 | 0001628280-26-062740 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Hyong Kim 2026-10-06 | Form 4 | 2026-10-07 | 0001628280-26-065321 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 06, 2026 vote | Form 8-K | 2026-06-09 | 0001628280-26-041926 | Item 5.07 · say-on-pay result. As reported: 94.82% (votes for as printed: 169,068,300). Filing ↗ |
| 60 | Section 06, 2025 vote | Form 8-K | 2025-06-11 | 0001628280-25-030795 | Item 5.07 · say-on-pay result. As reported: 98.59% (votes for as printed: 162,732,057). Filing ↗ |
| 61 | Section 06, 2024 vote | Form 8-K | 2024-06-13 | 0001628280-24-027889 | Item 5.07 · say-on-pay result. As reported: 86.67% (votes for as printed: 138,403,746). Filing ↗ |
| 62 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 63 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 64 | Section 09b board cost (computed) | Computed | — | — | Cash 710,000 + equity 1,990,000 + all other 0 = 2,700,000, summed across the director compensation table rows.machine: formula: Σ = 2,700,000 |
| 65 | Bausch & Lomb Corp., Section 10b CEO total | DEF 14A | 2026-04-10 | 0001140361-26-014234 | CEO total compensation as printed in Bausch & Lomb Corp.'s own proxy. As printed: 32,194,326. Filing ↗machine: r2 · c27 · span 1103747–1103757 |
| 66 | DaVita Inc., Section 10b CEO total | DEF 14A | 2026-04-22 | 0000927066-26-000053 | CEO total compensation as printed in DaVita Inc.'s own proxy. As printed: 18,210,597. Filing ↗machine: r2 · c45 · span 800715–800725 |
| 67 | Quest Diagnostics Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001140361-26-013356 | CEO total compensation as printed in Quest Diagnostics Inc.'s own proxy. As printed: 15,498,479. Filing ↗machine: r2 · c17 · span 699327–699337 |
| 68 | Astrana Health, Inc., Section 10b CEO total | DEF 14A | 2026-04-17 | 0001104659-26-044536 | CEO total compensation as printed in Astrana Health, Inc.'s own proxy. As printed: 14,930,231. Filing ↗machine: span 525189–525199 |
| 69 | Evolent Health, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177267 | CEO total compensation as printed in Evolent Health, Inc.'s own proxy. As printed: 14,240,154. Filing ↗machine: r3 · c20 · span 908544–908555 |
| 70 | Ensign Group, Inc., Section 10b CEO total | DEF 14A | 2026-04-02 | 0001125376-26-000014 | CEO total compensation as printed in Ensign Group, Inc.'s own proxy. As printed: 13,804,700. Filing ↗machine: span 521316–521326 |
| 71 | RadNet, Inc., Section 10b CEO total | DEF 14A | 2026-04-20 | 0001683168-26-003086 | CEO total compensation as printed in RadNet, Inc.'s own proxy. As printed: 12,087,934. Filing ↗machine: t93 · r1 · c26 · span 428610–428620 |
| 72 | Alignment Healthcare (subject), Section 10b CEO total | DEF 14A | 2026-04-24 | 0001628280-26-027058 | CEO total compensation as printed in Alignment Healthcare's own proxy. As printed: 11,278,583. Filing ↗machine: r2 · c21 · span 656828–656838 |
| 73 | Teladoc Health, Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001477449-26-000020 | CEO total compensation as printed in Teladoc Health, Inc.'s own proxy. As printed: 11,202,996. Filing ↗machine: t167 · r2 · c16 · span 1057476–1057486 |
| 74 | Privia Health Group, Inc., Section 10b CEO total | DEF 14A | 2026-04-02 | 0001193125-26-138997 | CEO total compensation as printed in Privia Health Group, Inc.'s own proxy. As printed: 10,472,698. Filing ↗machine: t166 · r3 · c39 · span 538905–538915 |
| 75 | AdaptHealth Corp., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001628280-26-027965 | CEO total compensation as printed in AdaptHealth Corp.'s own proxy. As printed: 10,256,240. Filing ↗machine: r2 · c48 · span 476441–476451 |
| 76 | Option Care Health, Inc., Section 10b CEO total | DEF 14A | 2026-04-08 | 0001140361-26-013825 | CEO total compensation as printed in Option Care Health, Inc.'s own proxy. As printed: 9,266,330. Filing ↗machine: r2 · c25 · span 1114074–1114083 |
| 77 | agilon health, inc., Section 10b CEO total | DEF 14A | 2026-04-22 | 0001628280-26-026544 | CEO total compensation as printed in agilon health, inc.'s own proxy. As printed: 5,610,878. Filing ↗machine: r5 · c9 · span 1591317–1591326 |
| 78 | Select Medical Holdings Corp., Section 10b CEO total | DEF 14A | 2026-03-04 | 0001104659-26-023205 | CEO total compensation as printed in Select Medical Holdings Corp.'s own proxy. As printed: 3,042,527. Filing ↗machine: r13 · c41 · span 384685–384694 |
| 79 | Pediatrix Medical Group, Inc., Section 10b CEO total | DEF 14A | 2026-03-27 | 0001193125-26-127299 | CEO total compensation as printed in Pediatrix Medical Group, Inc.'s own proxy. As printed: 2,775,881. Filing ↗machine: r22 · c24 · span 1960691–1960700 |
| 80 | Clover Health Investments Corp., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001801170-26-000102 | CEO total compensation as printed in Clover Health Investments Corp.'s own proxy. As printed: 1,319,385. Filing ↗machine: t30 · r2 · c22 · span 493279–493288 |
| 81 | Oscar Health, Inc., Section 10b CEO total | DEF 14A | 2026-04-22 | 0001140361-26-016119 | CEO total compensation as printed in Oscar Health, Inc.'s own proxy. As printed: 1,149,308. Filing ↗machine: t173 · r2 · c25 · span 1052592–1052601 |
| 82 | Section 10a, Evolent Health, Inc. reciprocity | DEF 14A | — | 0001193125-26-177267 | Evolent Health, Inc.'s most recent proxy was read; its disclosed peer group does not include Alignment Healthcare. Filing ↗ |
| 83 | Section 10a, Clover Health Investments Corp. reciprocity | DEF 14A | — | 0001801170-26-000102 | Clover Health Investments Corp.'s most recent proxy was read; its disclosed peer group does not include Alignment Healthcare. Filing ↗ |
| 84 | Section 10a, RadNet, Inc. reciprocity | DEF 14A | — | 0001683168-26-003086 | RadNet, Inc.'s most recent proxy was read; its disclosed peer group does not include Alignment Healthcare. Filing ↗ |
| 85 | Section 10a, Oscar Health, Inc. reciprocity | DEF 14A | — | 0001140361-26-016119 | Oscar Health, Inc.'s most recent proxy was read; its disclosed peer group does not include Alignment Healthcare. Filing ↗ |
| 86 | Section 10a, AdaptHealth Corp. reciprocity | DEF 14A | — | 0001628280-26-027965 | AdaptHealth Corp. names Alignment Healthcare in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 87 | Section 10a, Option Care Health, Inc. reciprocity | DEF 14A | — | 0001140361-26-013825 | Option Care Health, Inc.'s most recent proxy was read; its disclosed peer group does not include Alignment Healthcare. Filing ↗ |
| 88 | Section 10a, agilon health, inc. reciprocity | DEF 14A | — | 0001628280-26-026544 | agilon health, inc. names Alignment Healthcare in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 89 | Section 10a, Bausch & Lomb Corp. reciprocity | DEF 14A | — | 0001140361-26-014234 | Bausch & Lomb Corp.'s most recent proxy was read; its disclosed peer group does not include Alignment Healthcare. Filing ↗ |
| 90 | Section 10a, Privia Health Group, Inc. reciprocity | DEF 14A | — | 0001193125-26-138997 | Privia Health Group, Inc. names Alignment Healthcare in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 91 | Section 10a, Quest Diagnostics Inc. reciprocity | DEF 14A | — | 0001140361-26-013356 | Quest Diagnostics Inc.'s most recent proxy was read; its disclosed peer group does not include Alignment Healthcare. Filing ↗ |
| 92 | Section 10a, DaVita Inc. reciprocity | DEF 14A | — | 0000927066-26-000053 | DaVita Inc.'s most recent proxy was read; its disclosed peer group does not include Alignment Healthcare. Filing ↗ |
| 93 | Section 10a, Ensign Group, Inc. reciprocity | DEF 14A | — | 0001125376-26-000014 | Ensign Group, Inc.'s most recent proxy was read; its disclosed peer group does not include Alignment Healthcare. Filing ↗ |
| 94 | Section 10a, Teladoc Health, Inc. reciprocity | DEF 14A | — | 0001477449-26-000020 | Teladoc Health, Inc. names Alignment Healthcare in its own disclosed peer group (read from its most recent proxy). Filing ↗ |